Carole Ho
Net Worth

Last updated:

What is Carole Ho net worth?

The estimated net worth of Dr. Carole Ho is at least $21,079,890 as of 25 Nov 2024. He owns shares worth $1,758,388 as insider, has earned $13,475,942 from insider trading and has received compensation worth at least $5,845,560 in Denali Therapeutics Inc..

What is the salary of Carole Ho?

Dr. Carole Ho salary is $835,080 per year as Chief Medical Officer & Head of Devel. in Denali Therapeutics Inc..

How old is Carole Ho?

Dr. Carole Ho is 52 years old, born in 1973.

What stocks does Carole Ho currently own?

As insider, Dr. Carole Ho owns shares in one company:

Company Title Shares Price per share Total value
Denali Therapeutics Inc. (DNLI) Chief Medical Officer & Head of Devel. 118,810 $14.8 $1,758,388

What does Denali Therapeutics Inc. do?

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

DNLI logo
DNLI
Denali Therapeutics Inc.
$14.8

Carole Ho insider trading

Denali Therapeutics Inc.

Dr. Carole Ho has made 69 insider trades between 2018-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 35,000 units of DNLI stock on 15 Nov 2018. As of 25 Nov 2024 he still owns at least 118,810 units of DNLI stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (right to buy) 17,845 $0.68 $12,135
Option
Common Stock 17,845 $0.68 $12,135
Sale
Common Stock 5,907 $24.96 $147,439
Sale
Common Stock 14,098 $24.41 $344,132
Sale
Common Stock 2,453 $23.79 $58,357
Sale
Common Stock 2,337 $22.89 $53,494
Sale
Common Stock 1,405 $17.79 $24,995
Sale
Common Stock 2,784 $17.29 $48,135
Sale
Common Stock 4,668 $19.02 $88,785
Sale
Common Stock 9,972 $19.43 $193,756
Sale
Common Stock 2,522 $23.22 $58,561
Sale
Common Stock 2,478 $22.6 $56,003
Sale
Common Stock 2,768 $23.79 $65,851
Sale
Common Stock 2,857 $24.15 $68,997
Sale
Common Stock 1,476 $29.4 $43,394
Sale
Common Stock 2,548 $30.1 $76,695
Sale
Common Stock 818 $29.8 $24,376
Sale
Common Stock 1,521 $30.88 $46,968
Sale
Common Stock 1,459 $28.48 $41,552
Sale
Common Stock 1,451 $28.67 $41,600
Sale
Common Stock 2,636 $28.44 $74,968
Sale
Common Stock 2,913 $28.69 $83,574
Sale
Common Stock 2,424 $31.98 $77,520
Sale
Common Stock 2,576 $33.22 $85,575
Sale
Common Stock 2,918 $34.71 $101,284
Sale
Common Stock 1,423 $37.1 $52,792
Sale
Common Stock 2,845 $44.78 $127,399
Sale
Common Stock 1,476 $42.52 $62,760
Sale
Common Stock 6,143 $48.91 $300,454
Sale
Common Stock 2,546 $49.61 $126,307
Sale
Common Stock 2,822 $54.62 $154,126
Sale
Common Stock 7,092 $67.94 $481,802
Sale
Common Stock 7,092 $67.94 $481,802
Sale
Common Stock 7,092 $67.94 $481,802
Sale
Common Stock 7,092 $67.94 $481,802
Sale
Common Stock 3,156 $70.83 $223,527
Sale
Common Stock 1,470 $75.17 $110,497
Sale
Common Stock 1,470 N/A N/A
Option
Restricted Stock Units 4,250 N/A N/A
Option
Common Stock 4,250 N/A N/A
Option
Common Stock 30,000 $5.28 $158,400
Sale
Common Stock 30,000 $41.1 $1,232,850
Option
Stock Option (right to buy) 30,000 $5.28 $158,400
Option
Common Stock 22,906 $40.12 $918,989
Option
Stock Option (right to buy) 22,906 $2.64 $60,472
Sale
Common Stock 22,906 $40.12 $918,989
Sale
Common Stock 3,689 $31 $114,359
Option
Restricted Stock Units 5,643 N/A N/A
Option
Common Stock 5,643 N/A N/A
Sale
Common Stock 1,428 $19.48 $27,817
Option
Common Stock 4,250 N/A N/A
Option
Restricted Stock Units 4,250 N/A N/A
Sale
Common Stock 3,464 $20.01 $69,315
Sale
Common Stock 860 $20 $17,200
Sale
Common Stock 2,566 $20 $51,320
Option
Common Stock 5,643 N/A N/A
Option
Restricted Stock Unites 5,643 N/A N/A
Sale
Common Stock 13,593 $15.46 $210,107
Option
Common Stock 6,511 $12.92 $84,090
Option
Stock Option (right to buy) 6,511 $12.92 $84,090
Sale
Common Stock 13,594 $12.03 $163,536
Option
Stock Option (right to buy) 4,617 $12.05 $55,612
Option
Common Stock 4,617 $12.05 $55,612
Option
Stock Option (right to buy) 2,546 $22.17 $56,445
Option
Common Stock 2,546 $22.17 $56,445
Sale
Common Stock 5,862 $22.17 $129,931
Option
Stock Option (right to buy) 2,653 $5.28 $14,008
Option
Common Stock 2,653 $5.28 $14,008
Sale
Common Stock 5,863 $23.22 $136,156
Sale
Common Stock 5,775 $14.4 $83,131
Option
Stock Option (right to buy) 2,613 $5.28 $13,797
Option
Common Stock 2,613 $5.28 $13,797
Sale
Common Stock 9,588 $26.62 $255,233
Option
Common Stock 5,862 $5.28 $30,951
Option
Stock Option (right to buy) 11,724 $5.28 $61,903
Sale
Common Stock 15,450 $26.54 $410,043
Option
Stock Option (right to buy) 12,377 $5.28 $65,351
Sale
Common Stock 18,380 $24.87 $457,019
Option
Common Stock 12,377 $5.28 $65,351
Option
Common Stock 5,775 $5.28 $30,492
Option
Stock Option (right to buy) 5,775 $5.28 $30,492
Sale
Common Stock 5,775 $5.28 $30,492
Option
Stock Option (right to buy) 500 $5.28 $2,640
Option
Common Stock 500 $5.28 $2,640
Sale
Common Stock 1,000 $5.28 $5,280
Sale
Common Stock 5,862 $21.96 $128,730
Option
Common Stock 5,862 $21.96 $128,730
Option
Stock Option (right to buy) 5,862 $21.96 $128,730
Sale
Common Stock 5,863 $22.36 $131,067
Option
Common Stock 5,863 $5.28 $30,957
Option
Stock Option (right to buy) 5,863 $5.28 $30,957
Option
Common Stock 5,775 $5.28 $30,492
Sale
Common Stock 5,775 $22.55 $130,197
Option
Stock Option (right to buy) 5,775 $5.28 $30,492
Option
Common Stock 7,856 $18.83 $147,928
Sale
Common Stock 7,856 $18.83 $147,928
Option
Stock Option (right to buy) 7,856 $18.83 $147,928
Option
Stock Option (right to buy) 3,869 $5.28 $20,428
Option
Common Stock 3,869 $5.28 $20,428
Sale
Common Stock 3,869 $18.8 $72,737
Sale
Common Stock 5,775 $5.28 $30,492
Option
Common Stock 5,775 $5.28 $30,492
Option
Stock Option (right to buy) 5,775 $5.28 $30,492
Option
Stock Option (right to buy) 11,900 $5.28 $62,832
Option
Common Stock 11,900 $5.28 $62,832
Sale
Common Stock 11,900 $19.67 $234,014
Option
Stock Option (right to buy) 11,550 $5.28 $60,984
Sale
Common Stock 8,552 $12.09 $103,394
Option
Common Stock 11,550 $5.28 $60,984
Sale
Common Stock 11,550 $19.84 $229,094
Option
Common Stock 5,775 $5.28 $30,492
Option
Stock Option (right to buy) 5,775 $5.28 $30,492
Option
Common Stock 17,500 $5.28 $92,400
Option
Stock Option (right to buy) 17,500 $5.28 $92,400
Sale
Common Stock 35,000 $18.8 $657,860
Sale
Common Stock 17,500 $18.8 $328,930
Option
Stock Option (right to buy) 12,235 $5.28 $64,601
Sale
Common Stock 17,500 $18.07 $316,155
Sale
Common Stock 35,000 $18.07 $632,310
Option
Common Stock 12,235 $5.28 $64,601
Sale
Common Stock 17,500 $21.72 $380,100
Sale
Common Stock 17,500 $19.05 $333,375
Sale
Common Stock 17,500 $18.04 $315,700

Denali Therapeutics key executives

Denali Therapeutics Inc. executives and other stock owners filed with the SEC: